Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 19, 2020 at 10:52 AM.

  1. #1 cafead, Nov 19, 2020 at 10:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, SVP of finance. Speaking at the Stifel 2020 Virtual Healthcare Conference in mid-November, he cited reductions as high as 78%.

    article source
     
    Quote

Reply to Thread